UPDATE: Goldman Sachs Downgrades Seres Therapeutics (MCRB) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seres Therapeutics (MCRB) PT Lowered to $18 at Oppenheimer, Following CLinical Business Update
July 22, 2021 4:17 PM EDTOppenheimer analyst Mark Breidenbach lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $18.00 (from $36.00) while maintaining a Outperform rating.
... MoreSeres Therapeutics (MCRB) PT Lowered to $21 at Jefferies, Following Clinical Business Update
July 22, 2021 2:18 PM EDTJefferies analyst Brian Mills lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $21.00 (from $41.00) while maintaining a Buy rating.
... MoreSeres Therapeutics (MCRB) PT Lowered to $32 at Piper Sandler, Following Clinical Business Update
July 22, 2021 12:42 PM EDTPiper Sandler analyst Edward A. Tenthoff lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $32.00 (from $40.00) while maintaining a Overweight rating.
... MoreSeres Therapeutics (MCRB) SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis Did Not Meet its Primary Endpoint
July 22, 2021 7:04 AM EDTSeres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did not meet its primary endpoint of improving clinical remission rates compared... More
